SAN

76.31

-1.27%↓

ARGX

765

+0.79%↑

SHL.DE

34.95

+0.26%↑

PHIA

22.42

-1.67%↓

FRE

37.73

+0.77%↑

SAN

76.31

-1.27%↓

ARGX

765

+0.79%↑

SHL.DE

34.95

+0.26%↑

PHIA

22.42

-1.67%↓

FRE

37.73

+0.77%↑

SAN

76.31

-1.27%↓

ARGX

765

+0.79%↑

SHL.DE

34.95

+0.26%↑

PHIA

22.42

-1.67%↓

FRE

37.73

+0.77%↑

SAN

76.31

-1.27%↓

ARGX

765

+0.79%↑

SHL.DE

34.95

+0.26%↑

PHIA

22.42

-1.67%↓

FRE

37.73

+0.77%↑

SAN

76.31

-1.27%↓

ARGX

765

+0.79%↑

SHL.DE

34.95

+0.26%↑

PHIA

22.42

-1.67%↓

FRE

37.73

+0.77%↑

Kodu・Aktsiate loetelu・Laboratorios Farmaceuticos Rovi SA
Search

Laboratorios Farmaceuticos Rovi SA

Suletud

SektorTervishoid

58.4 1.04

Osta

Hinna uuendus 10. juuni 2026, 15:24 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

57.65

Max

58.55

Põhinäitajad

By Trading Economics

Sissetulek

-33M

9.5M

Müük

-66M

152M

P/E

Sektori keskmine

24.641

49.052

Aktsiakasum

0.185

Kasumimarginaal

6.216

Töötajad

1,950

EBITDA

-45M

18M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+27.78% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

23. juuli 2026

Turustatistika

By TradingEconomics

Turukapital

-1.1B

3B

Eelmine avamishind

57.36

Eelmine sulgemishind

58.4

Uudiste sentiment

By Acuity

50%

50%

154 / 344 Pingereas Healthcare

Laboratorios Farmaceuticos Rovi SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. juuni 2026, 23:36 UTC

Tulu

Correction to Oracle Reports Higher 4Q Profit Article

DJ

Loe

10. juuni 2026, 23:19 UTC

Kuumad aktsiad

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

DJ

Loe

10. juuni 2026, 23:09 UTC

Suurimad hinnamuutused turgudel

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

DJ

Loe

10. juuni 2026, 23:04 UTC

Tulu

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

DJ

Loe

10. juuni 2026, 20:44 UTC

Suurimad hinnamuutused turgudel

Caterpillar Raises Quarterly Dividend 8%

DJ

Loe

10. juuni 2026, 23:49 UTC

Omandamised, ülevõtmised, äriostud

Elliott: Northern Star Should Take No Options Off The Table

DJ

Loe

10. juuni 2026, 23:48 UTC

Omandamised, ülevõtmised, äriostud

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

DJ

Loe

10. juuni 2026, 23:48 UTC

Omandamised, ülevõtmised, äriostud

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

DJ

Loe

10. juuni 2026, 23:47 UTC

Market Talk

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

DJ

Loe

10. juuni 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

DJ

Loe

10. juuni 2026, 23:46 UTC

Omandamised, ülevõtmised, äriostud

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

DJ

Loe

10. juuni 2026, 23:38 UTC

Market Talk

Global Equities Roundup: Market Talk

DJ

Loe

10. juuni 2026, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

DJ

Loe

10. juuni 2026, 23:38 UTC

Market Talk

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

DJ

Loe

10. juuni 2026, 23:32 UTC

Market Talk

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

DJ

Loe

10. juuni 2026, 23:20 UTC

Market Talk

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

DJ

Loe

10. juuni 2026, 22:05 UTC

Market Talk

Correction to Bank of Canada Stays on Hold Market Talk

DJ

Loe

10. juuni 2026, 21:57 UTC

Tulu

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Loe

10. juuni 2026, 21:52 UTC

Tulu

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Loe

10. juuni 2026, 21:35 UTC

Tulu

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Loe

10. juuni 2026, 21:22 UTC

Tulu

Oracle Stock Slides on Increased Capital Spending -- WSJ

DJ

Loe

10. juuni 2026, 20:50 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

DJ

Loe

10. juuni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

DJ

Loe

10. juuni 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

DJ

Loe

10. juuni 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

DJ

Loe

10. juuni 2026, 20:39 UTC

Market Talk
Tulu

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

DJ

Loe

10. juuni 2026, 20:34 UTC

Tulu

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Loe

10. juuni 2026, 20:33 UTC

Tulu

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

DJ

Loe

10. juuni 2026, 20:33 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

DJ

Loe

10. juuni 2026, 20:33 UTC

Market Talk
Tulu

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

DJ

Loe

Võrdlus sarnastega

Hinnamuutus

Laboratorios Farmaceuticos Rovi SA Prognoos

Hinnasiht

By TipRanks

27.78% tõus

12 kuu keskmine prognoos

Keskmine 73.6 EUR  27.78%

Kõrge 83 EUR

Madal 64.2 EUR

Põhineb 2 Wall Streeti analüütiku instrumendi Laboratorios Farmaceuticos Rovi SA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

1

Osta

1

Hoia

0

Müü

Põhineb 2 analüütiku instrumendi Laboratorios Farmaceuticos Rovi SA aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

154 / 344 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.

Muud aktsiad sektorist

SAN

Sanofi SA

76.31

↓-1.27%

ARGX

Argenx SE

765

↑ +0.79%

SHL.DE

Siemens Healthineers AG

34.95

↑ +0.26%

PHIA

Koninklijke Philips NV

22.42

↓-1.67%

FRE

Fresenius SE & Co KGaA

37.73

↑ +0.77%
help-icon Live chat